The World Health Organization (WHO) just spread the first figures AstraZeneca / Oxford and Pfizer Vaccine Doses coronavirus that are being assigned to countries participants of the international COVAX system, such as Argentina.
In this first distribution, Our country has assigned 2,275,200 doses of the product from AstraZeneca and the University of Oxford for the first half of the year, provided that the process of including the vaccine in the WHO emergency use list is completed, which the authorities estimate will occur in the coming days.
The international COVAX program of WHO released figures for COVID-19 vaccine doses to be shipped to 92 low- and middle-income countries starting in June, said from the WHO itself and the GAVI alliance.
Total, 192 countries have joined COVAX, an initiative launched last April with the aim of providing equitable access to immunization against the pandemic. The GAVI alliance, WHO, the Coalition for Epidemic Preparedness and Innovation and UNICEF will publish their “preliminary distribution forecast,” GAVI reported.
The list released details the distribution for the first two quarters of the year, allocating 240 million doses of the AstraZeneca / Oxford vaccine produced at the Serum Institute of India (SII) and another 96 million doses from the same laboratory included in a agreement signed with the Gavi Alliance for Vaccines.
GAVI CEO Seth Berkley said last week that COVAX aims to deliver 2.3 billion doses by the end of this year, including 1.8 billion doses to lower-income countries at no cost to their governments.
UNICEF, the only fund that has bought the most vaccines in the world, expects a “crisis” in demand in the first half of the year and that supplies begin to be distributed more normally in the second half, said its chief executive, Henrietta Fore, on Friday.
The vaccine crisis is patent in some areas of the world and has worsened after the European Union announced a ban on the export of vaccines after AstraZeneca cut the supplies available to the bloc until March due to production delays.
A unique vaccine delivery system
The Global Access Fund for COVID-19 Vaccines (COVAX) is a public-private initiative to promote equitable access to coronavirus vaccines in the world. So far, COVAX is the only global project of its kind. Its goal is to ensure that the vaccine reaches as many people as possible globally quickly and fairly, providing doses to countries that could not afford its market price. All participating countries will have access to vaccines in proportion to their population, regardless of their socioeconomic status.
International funders got together in early June last year and raised funds for an ambitious venture: buy enough COVID-19 vaccines to immunize 20% of the most vulnerable people worldwide, have a variety of diversified doses, deliver them as soon as they are available, rebuild economies and ease the acute phase of the pandemic. High- and middle-income countries contribute to the fund and receive a portion of the vaccines purchased, and the poorest countries receive them free of charge.
They will begin to be distributed in the first half of this year to participating countries, including several from Latin America. Among the new agreements added to the initiative, which seeks to ensure equitable access to immunizations, there is one with AstraZeneca / Oxford for 170 million doses and another with Johnson & Johnson for 500 million doses. UNICEF announced that it is now ready to transport up to 850 tons of COVID-19 vaccines per month throughout 2021.
High-income countries have been purchasing large quantities of current and future vaccine doses directly from suppliers. Middle-income countries are also negotiating their own supplies. This has left relatively few vaccines for COVAX, which needs to deliver 2 billion doses by the end of this year to reach its goal.
Most of the 10 vaccine producers with whom they have reached agreements, have guaranteed access to a portion of the first batch of vaccines and greater volume to greater production. “Our goal is to start distributing in the first quarter of 2021, but it will depend on three things. Availability of vaccines, approval of regulatory authorities. And finally, the countries are readyBerkley de Gavi concluded.
I KEEP READING: